%0 Journal Article
%T Severe, Symptomatic Hypocalcemia due to Denosumab Administration: Treatment and Clinical Course
%A Jarred Strickling
%A Michael J. Wilkowski
%J Archive of "Case Reports in Nephrology and Dialysis".
%D 2019
%R 10.1159/000499824
%X Denosumab is a receptor activator of nuclear factor kappa-B (RANK) ligand inhibitor used in the treatment of osteoporosis. Blockade of RANK ligand prevents osteoclastic resorption of bone, but in doing so impairs the parathyroid hormone (PTH)-driven maintenance of serum calcium. A subsequent elevation of PTH remains active at sites other than bone, potentially lowering serum phosphate by inhibiting proximal tubular reabsorption. We present 2 patients who developed severe, symptomatic hypocalcemia after administration of denosumab. These patients provide an opportunity to describe the clinical course and treatment, including the need to consider a continuous calcium infusion, of severe, symptomatic hypocalcemia caused by denosumab
%K Denosumab
%K Hypocalcemia
%K Therapy
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6514500/